Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Issue 32 (31st July 2015) - Wu, Ting
Highlights A dose-ranging study of a novel E. coli-expressed HPV 16/18 vaccine candidate. This is the first study of the immunogenicity of this recombinant HPV 16/18 vaccine. This vaccine was well-tolerated and appeared immunogenic in young women aged 18–25.